Artrya vs Caristo Diagnostics (2026)
These two answer different questions from the same coronary CT angiogram. Artrya's Salix is a reading platform: physicians start from an automated analysis of anatomy, stenosis and plaque and edit it before reporting. Caristo's CaRi-Heart measures something a standard read does not report, coronary inflammation, and turns it into a 10 year cardiac mortality risk estimate. Both are now authorized in the US. Salix Coronary Plaque was cleared in August 2025 (K251837), and CaRi-Heart received De Novo authorization in July 2026 (DEN250042), with US launch from the third quarter. Artrya publishes test data for its machine learning outputs on centers held out from training. Caristo's evidence for the risk score comes from its founders' Oxford cohorts, ORFAN and CRISP-CT. If you need a faster way to read and report the scan, start with Artrya. If you want inflammation risk on scans you already read, start with Caristo.
- You want to read coronary CT in house: Salix returns an automated analysis in minutes, without an external reading team, and physicians edit it before reporting.
- You want to see the test data: the K251837 summary names which outputs are machine learning and tests them on centers held out from training, with 302 series for calcium and 107 for segmentation.
- You want to size the cost before a call: an ASX filing gives US$0.6 million over five years for Tanner Health's five hospitals, plus a per scan plaque fee that is not published.
- You want a measurement a standard read does not give: CaRi-Heart quantifies coronary inflammation from the routine scan and estimates 10 year cardiac mortality risk.
- Your patients have no obstructive disease: ORFAN and CRISP-CT, both in The Lancet, link higher inflammation scores to cardiac events in that group too.
- You want the limits in writing: the Instructions for Use are published openly, with cautions, age and imaging limits and the trained operator step.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Artrya and Caristo Diagnostics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Artrya | Caristo Diagnostics |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Headquarters | Perth, Western Australia, Australia | Oxford, England, United Kingdom |
| Website | artrya.com | caristo.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Artrya, listed on the ASX (AYA) and based in Perth, sells Salix, a cloud platform for reading coronary CT angiography at the point of care. Physicians start from an automated analysis, returned in minutes without an external reading team, and edit it before reporting. Machine learning handles centerline extraction, vessel labeling, lumen and wall segmentation and calcium scoring, and plaque is quantified from Hounsfield unit ranges, including low attenuation plaque, spotty calcification, positive remodeling and the napkin-ring sign.
Source: AI Health Index, September 2026
Caristo Diagnostics, an Oxford spinout, measures coronary inflammation from the same routine coronary CT angiogram used to assess plaque. Inflammation changes the fat around the coronary arteries in a way CT can detect; CaRi-Heart uses AI to quantify it as the FAI-Score and to estimate 10 year cardiac mortality risk (the CaRi-Heart Risk score).
Source: AI Health Index, September 2026
Questions buyers ask
How do Artrya and Caristo Diagnostics work with the EHR?
Artrya's announcement of its Tanner Health contract says Salix Coronary Anatomy was integrated into Tanner's PACS and electronic medical record and is in clinical use across its five hospitals; Northeast Georgia Health System and Cone Health are further customers. Salix reads DICOM from any CT scanner, and new modules such as Coronary Plaque switch on inside the same interface without a separate integration project.
CaRi-Plaque receives CT images from the hospital's PACS by secure transmittal (DICOM), and Caristo returns a report to the healthcare professional, with an optional primary care summary report; turnaround is set by contract and can be delayed. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How are Artrya and Caristo Diagnostics priced and sold?
Artrya's ASX announcement of its first US customer states a five year SaaS license for Salix Coronary Anatomy at a monthly subscription fee, valued at US$0.6 million over 60 months for Tanner Health's five hospitals and 30 practices, with a fee per scan added for Coronary Plaque and, once cleared, Coronary Flow. Further US customers are reported on the same subscription plus per scan structure.
For Caristo Diagnostics, the AMA assigned Category III CPT codes 0992T and 0993T for CaRi-Heart from January 2026; Category III codes track emerging technology and carry no set national payment, so coverage is decided payer by payer. CaRi-Plaque falls under the Category I code for AI plaque analysis. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How do Artrya and Caristo Diagnostics handle patient data?
With Artrya, no retention period is given, and because the default instruction is not to put personal information into the product at all, it is unclear which document actually governs an identified coronary CT study. The same policy separately permits disclosure to a third party who may combine data to develop anonymized consumer insights, and lists advertising and marketing among its purposes, with no clinical carve out.
In Caristo Diagnostics' case, a Data Protection Officer is appointed and named, international transfer safeguards are set out in real detail including adequacy decisions and standard contractual clauses, ISO 27001 certification backs the technical controls, and third party deidentification services are disclosed among the providers relied upon. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Which settings and specialties do Artrya and Caristo Diagnostics cover?
For Artrya, the cleared indication covers adjunctive analysis of CCTA for patients evaluated for known or suspected coronary disease and calcium scoring on non-contrast cardiac CT, on any CT scanner. The validation in K251837 spans seven US centers, four scanner makers, adults aged 23 to 84 and routine clinician readers.
With Caristo Diagnostics, the site also markets preventive screening, drug trial endpoints and intervention planning, which that validation does not cover. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
CaRi-Heart's De Novo authorization dates from July 2026, and Caristo has not yet published the US indication or its conditions. The ORFAN and CRISP-CT evidence comes from the Oxford group that founded the company. Artrya markets Salix for rapid chest pain assessment in emergency and primary care, beyond its adjunctive clearance, and its SAPPHIRE study has not yet reported. Neither vendor publishes a per scan price.